Q2 2023 · 13F-HR
Foresite Capital Management IV, LLCholdings as filed
Filed 2023-08-11 · accession 0001104659-23-090055
$203.4M
Reported value
7
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N69605108 | PHVS | Pharvaris N.V. | $56.7M | 27.9% | 3,743,450 | Common | SOLE |
| 55083R104 | — | Lyell Immunopharma, Inc. | $30.8M | 15.2% | 9,700,000 | Common | SOLE |
| 49705R105 | KNTEUSD | Kinnate Biopharma Inc. | $29.3M | 14.4% | 9,671,643 | Common | SOLE |
| 00461U105 | ACRS | Aclaris Therapeutics, Inc. | $29.1M | 14.3% | 2,808,034 | Common | SOLE |
| 50127T109 | KURA | Kura Oncology, Inc. | $19.6M | 9.62% | 1,849,947 | Common | SOLE |
| 23257D103 | CBAYUSD | Cymabay Therapeutics, Inc. | $19.6M | 9.62% | 1,787,094 | Common | SOLE |
| 87164F105 | SNDX | Syndax Pharmaceuticals, Inc. | $18.3M | 9.00% | 875,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.